Exelixis (EXEL)
(Delayed Data from NSDQ)
$29.35 USD
+0.85 (2.98%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $29.38 +0.03 (0.10%) 7:58 PM ET
2-Buy of 5 2
B Value C Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$29.35 USD
+0.85 (2.98%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $29.38 +0.03 (0.10%) 7:58 PM ET
2-Buy of 5 2
B Value C Growth A Momentum B VGM
Zacks News
Sarepta Stock More Than Doubles This Year So Far: Here's Why
by Zacks Equity Research
Sarepta's (SRPT) key product, Exondys 51, continues to perform well. Its lead pipeline candidate, golodirsen, is also making good progress. The company is also developing gene therapies.
Top Ranked Momentum Stocks to Buy for November 16th
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, November 16th
Exelixis, Ipsen Get EU Nod for Label Expansion of Cabometyx
by Zacks Equity Research
Exelixis (EXEL) and partner Ipsen receive EU approval for the label expansion of Cabometyx (cabozantinib) tablets as a monotherapy for HCC in adults.
Can Exelixis (EXEL) Run Higher on Rising Earnings Estimates?
by Zacks Equity Research
Exelixis (EXEL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Exelixis (EXEL) Q3 Earnings, Revenues Beat on Cabometyx Sales
by Zacks Equity Research
Exelixis's (EXEL) earnings and revenue beat expectations in the third-quarter propelled by strong sales of Cabometyx.
Exelixis (EXEL) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
Exelixis' (EXEL) third-quarter results are expected to benefit from Cabometyx performance and other pipeline updates.
Exelixis (EXEL) Q3 Earnings Preview: What to Expect
by Zacks Equity Research
Exelixis (EXEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why the Earnings Surprise Streak Could Continue for Exelixis (EXEL)
by Zacks Equity Research
Exelixis (EXEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Exelixis, Ipsen Receive Positive CHMP Opinion for Cabometyx
by Zacks Equity Research
Exelixis, Inc. (EXEL) and partner Ipsen get a positive opinion from the CHMP for Cabometyx tablets as a monotherapy for the second-line treatment of hepatocellular carcinoma in adults.
Exelixis' Partner Ipsen Gets Approval for Cabometyx in Canada
by Zacks Equity Research
Exelixis (EXEL) and partner Ipsen Biopharmaceuticals Canada gain approval for Cabometyx from Health Canada for the treatment of advanced renal cell carcinoma in adult patients.
Exelixis' Cabometyx Recommended by NCCN for All Types of RCC
by Zacks Equity Research
Exelixis' (EXEL) lead drug, Cabometyx gets updated recommendations from the NCCN.
Exelixis (EXEL) Down 14.1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Exelixis (EXEL) Earnings Beat on Strong Cabometyx in Q2
by Zacks Equity Research
Exelixis (EXEL) posts better-than-expected results for the second quarter, propelled by strong demand for Cabometyx. A milestone payment from Ipsen also boosts sales and earnings.
Exelixis (EXEL) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Exelixis (EXEL) delivered earnings and revenue surprises of 86.67% and 21.39%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Is Exelixis (EXEL) Poised for a Beat Again in Q2?
by Zacks Equity Research
Exelixis (EXEL) is likely to beat earnings again in the second quarter, driven by favourable metrics. Investors will focus on the company's uptake in the first-line RCC setting, along with other updates.
Roche's Tecentriq Gets Breakthrough Therapy Status for HCC
by Zacks Equity Research
The FDA grants breakthrough therapy designation to Roche's (RHHBY) key cancer drug, Tecentriq, in combination with Avastin for the first-line treatment of advanced HCC.
Exelixis (EXEL) Jumps: Stock Rises 8%
by Zacks Equity Research
Exelixis (EXEL) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
Biotech Stock Roundup: FDA Gives Nod to Amgen's Drugs, EU Approves Exelixis' Cabometyx
by Zacks Equity Research
Label expansion of a few prominent drugs along with pipeline updates were the key areas of focus for investors in the biotech space.
Exelixis' Cabometyx Gets EU Nod for First-Line Kidney Cancer
by Zacks Equity Research
European Commission approves Exelixis' (EXEL) Cabometyx 20 mg, 40 mg and 60 mg for the first-line treatment of adults with intermediate- or poor-risk renal cell carcinoma in the European Union.
Are Options Traders Betting on a Big Move in Exelixis (EXEL) Stock?
by Zacks Equity Research
Investors in Exelixis (EXEL) need to pay close attention to the stock based on moves in the options market lately.
Here's Why You Should Sell Fresenius Medical (FMS) Stock Now
by Zacks Equity Research
A rapidly changing healthcare environment in the United States, sluggish Q1 and competition in the niche markets are major headwinds for Fresenius Medical (FMS).
Radius Health (RDUS) Incurs Narrower-Than-Expected Q1 Loss
by Zacks Equity Research
Radius Health (RDUS) narrower-than-expected loss in the first quarter was encouraging as sales of lead drug Tymlos pick up amid competition.
Exelixis, Applied Optoelectronics and Nvidia as Zacks Bull and Bear of the Day
by Zacks Equity Research
Exelixis, Applied Optoelectronics and Nvidia as Zacks Bull and Bear of the Day
Here's Why You Should Invest in Varian Medical (VAR) Now
by Zacks Equity Research
Strong fundamentals and solid Q2 results make Varian Medical (VAR) a must buy.
Cerner EHR Range Picked by Indiana's FSSA for Patient Care
by Zacks Equity Research
Cerner (CERN) gains as Indiana FSSA chooses its flagship Cerner Millennium solutions to take better care of patients.